Home/Filings/4/0000950170-25-010594
4//SEC Filing

Somaiya Mayur Ian 4

Accession 0000950170-25-010594

CIK 0001936258other

Filed

Jan 28, 7:00 PM ET

Accepted

Jan 29, 5:25 PM ET

Size

17.7 KB

Accession

0000950170-25-010594

Insider Transaction Report

Form 4
Period: 2025-01-27
Somaiya Mayur Ian
Chief Financial Officer
Transactions
  • Sale

    Ordinary Shares

    2025-01-283,40538,000 total
  • Exercise/Conversion

    Option (Right to Buy)

    2025-01-2814,900762,814 total
    Exercise: $9.26Exp: 2033-11-01Ordinary Shares (14,900 underlying)
  • Exercise/Conversion

    Ordinary Shares

    2025-01-27$9.26/sh+46,983$435,06384,983 total
  • Sale

    Ordinary Shares

    2025-01-2733,67951,304 total
  • Sale

    Ordinary Shares

    2025-01-2811,49541,405 total
  • Exercise/Conversion

    Option (Right to Buy)

    2025-01-2746,983777,714 total
    Exercise: $9.26Exp: 2033-11-01Ordinary Shares (46,983 underlying)
  • Sale

    Ordinary Shares

    2025-01-2713,30438,000 total
  • Exercise/Conversion

    Ordinary Shares

    2025-01-28$9.26/sh+14,900$137,97452,900 total
Footnotes (6)
  • [F1]This transaction was effected pursuant to a trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  • [F2]These shares were sold in multiple transactions at prices ranging from $22.38 per share to $23.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  • [F3]These shares were sold in multiple transactions at prices ranging from $23.38 per share to $23.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  • [F4]These shares were sold in multiple transactions at prices ranging from $20.93 per share to $21.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  • [F5]These shares were sold in multiple transactions at prices ranging from $21.93 per share to $22.41 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  • [F6]The option was granted on November 1, 2023. 25% of the shares underlying the option vested on the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.

Documents

1 file

Issuer

NewAmsterdam Pharma Co N.V.

CIK 0001936258

Entity typeother

Related Parties

1
  • filerCIK 0001760303

Filing Metadata

Form type
4
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 5:25 PM ET
Size
17.7 KB